Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience

Neuromuscul Disord. 2017 Dec;27(12):1084-1086. doi: 10.1016/j.nmd.2017.09.006. Epub 2017 Sep 21.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Humans
  • Italy
  • Oligonucleotides / therapeutic use*
  • Spinal Muscular Atrophies of Childhood / drug therapy*
  • Survival of Motor Neuron 1 Protein / chemistry
  • Survival of Motor Neuron 1 Protein / metabolism*

Substances

  • Oligonucleotides
  • Survival of Motor Neuron 1 Protein
  • nusinersen